ADCT's Quality Score rose 1 point on Wed, Nov 4, to -3.
Follow ADCT's trial news. Pro members can get an alert when ADC Therapeutics SA files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 9% on Oct 13, and still 17% under its Oct 12 close.
“ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring.”
| Holding it back | Sales down 61% |
| Latest filing | 8-K, Nov 4 |
ReportToday after the close: the results are out. Past reports ›
ADCT closed +12.0% that day on 3.7x normal volume.
After its last 3 reports it closed -1.7% on average, higher 1 of 3 times.
The company says its cash lasts into 2029 (8-K, Nov 4).
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
ADCT is #198 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 198 |
Reports Mon Nov 9, before the open (in 5 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Increase in Product Revenues, net from sales of ZYNLONTA in the quarter and year - to - date periods were primarily attributable to an increase in sales volume”
ADCT's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
No outlook figures read from this release.
Sales fell 27% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 18% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 13, 2026 | -13.0% | -14.6% | -15.4% |
| May 4, 2026 | -6.5% | -3.9% | -8.6% |
| Mar 10, 2026 | +7.3% | +13.5% | -0.2% |
Sales grew in two of the last three years, to $81.4M in 2025. It lost money in each of the four years.
Officers and directors with a Form 4 in the last 12 months.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
“The biotechnology industry, and the oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”
ADCT scores -3 today, which Breakaway calls Poor. It is #198 of 291 in Biotech by Quality Score, with 5 of 14 chart checks firing. Down 9% on Oct 13, and still 17% under its Oct 12 close. Shares: 36.3% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ADCT scores -3 today, which Breakaway calls Poor (below zero). That is #198 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ADCT's -3.
Reports Mon Nov 9, before the open, a date the company confirmed. ADCT closed higher after 1 of its last 3 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.